BNIGF (Beroni Group) Cyclically Adjusted PS Ratio: 0.07 (As of Sep. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BNIGF Beroni Group Ltd BNIGF
4 GF Score
Price $0.01
View Full Analysis

What is Beroni Group Cyclically Adjusted PS Ratio?

Beroni Group BNIGF 4 Cyclically Adjusted PS Ratio is 0.07 as of Sep. 16, 2026. GuruFocus rates BNIGF with a GF Score™ of 4/100.

Beroni Group does not have a history long enough to calculate Cyclically Adjusted Revenue per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PS Ratio for this company.

Shiller PE for Stocks: The True Measure of Stock Valuation


Beroni Group  (OTCPK:BNIGF) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Beroni Group Cyclically Adjusted PS Ratio Related Terms


Beroni Group Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Beroni Group's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beroni Group Cyclically Adjusted PS Ratio Chart

Beroni Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 103.66

Beroni Group Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 103.66 8.63

BNIGF vs PNXP, CRYM, GCAN: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Beroni Group's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beroni Group Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Beroni Group's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Beroni Group's Cyclically Adjusted PS Ratio falls into.


BNIGF
4GF Score
Beroni Group Ltd BNIGF
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beroni Group Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Beroni Group does not have a history long enough to calculate Cyclically Adjusted Revenue per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PS Ratio for this company.

What does a Cyclically Adjusted PS Ratio of 0.07 mean?
Beroni Group (BNIGF) has a Cyclically Adjusted PS Ratio of 0.07 as of Sep. 16, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Beroni Group and its competitors.
Is Beroni Group's Cyclically Adjusted PS Ratio too high?
Beroni Group's current Cyclically Adjusted PS Ratio is 0.07. The Drug Manufacturers industry median Cyclically Adjusted PS Ratio is 2.00. Beroni Group's value of 0.07 is 96.5% below this industry median. Overall, Beroni Group has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does Beroni Group's Cyclically Adjusted PS Ratio compare to PNXP and CRYM?
Beroni Group's Cyclically Adjusted PS Ratio of 0.07 can be compared against companies in the Drug Manufacturers industry. The industry median Cyclically Adjusted PS Ratio is 2.00. Beroni Group's value of 0.07 is 96.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Drug Manufacturers company?
The median Cyclically Adjusted PS Ratio among Drug Manufacturers companies is 2.00, based on 755 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beroni Group's current Cyclically Adjusted PS Ratio of 0.07 is 96.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Beroni Group and its competitors. For the Drug Manufacturers industry, the median Cyclically Adjusted PS Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beroni Group's current Cyclically Adjusted PS Ratio is 0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beroni Group stock overvalued right now?
Beroni Group (BNIGF) has a current Cyclically Adjusted PS Ratio of 0.07. The current Cyclically Adjusted PS Ratio is 0.07 and 96.5% below the Drug Manufacturers industry median of 2.00. Beroni Group's overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Beroni Group (BNIGF), the current Cyclically Adjusted PS Ratio is 0.07 as of Sep. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Beroni Group Business Description

Address 175 Pitt Street, Level 16, Sydney, NSW, AUS, 2000
Beroni Group Ltd is an Australia based company engaged in the sales of smoking control product (NicoBloc), air purifier, water filter, healthcare products and supplements, cell therapies, stem-cell based cosmetics and viral diagnostic kits and also investing in the research and development of oncology drugs and therapies. It has organized its business into four core business areas: cell therapies, developing new anticancer drugs, an e-commerce platform for pharmaceutical and healthcare products, and detection & diagnosis of infectious diseases. Geographically, the company operates in China.
4GF Score

Get the complete analysis for BNIGF

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.01
Price